Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy - 26/08/11
Doi : 10.1016/j.amjcard.2004.04.028
David Aguilar, MD a, ⁎ 
, Samuel Z Goldhaber, MD b, Daniel J Gans, MS c, Andrew S Levey, MD d, Jerome G Porush, MD e, Julia B Lewis, MD f, Jean-Lucien Rouleau, MD g, Tomas Berl, MD h, Edmund J Lewis, MD i, Marc A Pfeffer, MD, PhD b
, Samuel Z Goldhaber, MD b, Daniel J Gans, MS c, Andrew S Levey, MD d, Jerome G Porush, MD e, Julia B Lewis, MD f, Jean-Lucien Rouleau, MD g, Tomas Berl, MD h, Edmund J Lewis, MD i, Marc A Pfeffer, MD, PhD bCollaborative Study Group
a Division of Cardiology, University of Texas Health Science Center, Houston, Texas, USA
b Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
c Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, USA
d Tufts-New England Medical Center, Boston, Massachusetts, USA
e Brookdale University Hospital and Medical Center, Brooklyn, New York, USA
f Vanderbilt University College of Medicine, Nashville, Tennessee, USA
g University of Montreal, Montreal, Quebec, Canada
h University of Colorado Medical School, Denver, Colorado, USA
i Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA
*Dr. Aguilar's address is: University of Texas Health Science Center, Department of Cardiology, 6431 Fannin, MSB 1.246, Houston, Texas 77030, USA.
Abstract |
During the Irbesartan Diabetic Nephropathy Trial, 1,387 participants with type 2 diabetes mellitus, hypertension, and nephropathy underwent serial electrocardiograms for the identification of Q-wave myocardial infarction (MI). During a mean follow-up of 2.5 years, 14 of 99 first nonfatal MIs in this group were clinically unrecognized, accounting for 14% of all first nonfatal MIs.
Le texte complet de cet article est disponible en PDF. | The Irbesartan Diabetic Nephropathy Trial was sponsored with grant support by Bristol-Myers Squibb Pharmaceutical Research Institute, Pennington, New Jersey, and Sanofi-Synthelabo, Inc., New York, New York. |
© 2004
Excerpta Medica Inc. Tous droits réservés.
Vol 94 - N° 3
P. 337-339 - août 2004 Retour au numéro
Article précédent
- Comparison of the extent and severity of coronary artery disease in patients with acute myocardial infarction with and without microalbuminuria
- Ioannis Lekatsas, Athanasios Kranidis, Georgios Ioannidis, Christos Kalofoutis, Antonios Tavernarakis, Nikolaos Thalassinos, Anastasios Kalofoutis, Lambros Anthopoulos, Spyridon Koulouris
- Usefulness of myocardial contrast echocardiography in predicting global left ventricular functional recovery after anterior wall acute myocardial infarction
- Michael L Main, Anthony Magalski, Lisa L Kusnetzky, Becky A Morris, Philip G Jones
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?